Molly Freeman on SBRT Aftercare for Patients with Lung Cancer

APPs provide an in-depth look at amivantamab plus lazertinib for the treatment of patients with locally advanced or metastatic non–small cell lung cancer.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Based on findings from a phase 2 expansion cohort, the FDA granted breakthrough therapy designation to sacituzumab tirumotecan for use in select patients with EGFR+ non–small cell lung cancer.

According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer survival; however, rates have improved in the last 5 years regardless.